Skip to main content
Figure 7 | Retrovirology

Figure 7

From: β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release

Figure 7

β-TrCP1/β-TrCP2-depleted TZM-bl cells support Vpu's ability to enhance HIV-1 release and to downregulate endogenous CD317, but not CD4. TZM-bl cells were transfected twice with combinations of siRNAs targeting β-TrCP1 and β-TrCP2 (siT1/2 1 : siRNAs for β-TrCP1+ β-TrCP2 1 , or siT1/2 2 : siRNAs for β-TrCP1+ β-TrCP2 2 ), or with a control siRNA (si Control). During the second transfection plasmids encoding (A) HIV-1wt or HIV-1Δvpu, or (B, C) GFP or Vpu.GFP were added. Two days post-transfection, (A) the yield of infectious HIV-1 in culture supernatants was quantified and is plotted relative to the cell-associated levels of p24CA with results for HIV-1 wt in control cells given as 100%. The arithmetic means ± SEM of three independent experiments are shown. (B, C) Relative surface levels of CD317 and CD4 on GFP-positive cells were quantified two days post-transfection by flow cytometry. Shown are arithmetic means ± SEM of three independent experiments. Student's-test (comparing results for HIV-1 wt and HIV-1Δvpu for each condition): * p = 0.01, ** p < 0.002, *** p < 10-4.

Back to article page